Media headlines about AbbVie (NYSE:ABBV) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AbbVie earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4319396047114 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Focus on Unusual Volume Mover: AbbVie Inc. (ABBV) – Wall Street Morning (wallstreetmorning.com)
- Zacks Investment Research Downgrades AbbVie (ABBV) to Hold (americanbankingnews.com)
- Obsessive-Compulsive Disorder – Pipeline Review, H2 2017 increasing demand with key players: AbbVie Inc, Addex … – Healthcare Journal (journalhealthcare.com)
- AbbVie Inc. (ABBV) : Investors may need a consensus Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- BRIEF-AbbVie Says CEO’s 2017 Total Compensations Were $22.63 Mln Vs $20.97 Mln In 2016 – Reuters (reuters.com)
AbbVie (ABBV) traded up $0.62 during trading hours on Tuesday, reaching $112.65. 4,933,785 shares of the company were exchanged, compared to its average volume of 6,710,733. AbbVie has a 52 week low of $63.12 and a 52 week high of $125.86. The company has a quick ratio of 1.18, a current ratio of 1.28 and a debt-to-equity ratio of 6.07. The company has a market cap of $180,568.41, a price-to-earnings ratio of 34.24, a P/E/G ratio of 1.07 and a beta of 1.52.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a net margin of 18.82% and a return on equity of 158.15%. The company had revenue of $7.74 billion during the quarter, compared to analyst estimates of $7.53 billion. During the same period in the prior year, the business posted $1.20 EPS. The firm’s revenue was up 13.9% compared to the same quarter last year. research analysts predict that AbbVie will post 7.48 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be issued a dividend of $0.96 per share. This is a positive change from AbbVie’s previous quarterly dividend of $0.71. This represents a $3.84 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Thursday, April 12th. AbbVie’s dividend payout ratio is currently 86.32%.
AbbVie announced that its board has approved a share buyback plan on Thursday, February 15th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its stock is undervalued.
Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday. BMO Capital Markets set a $95.00 target price on shares of AbbVie and gave the company a “sell” rating in a research report on Tuesday, March 13th. Vetr upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $128.42 target price for the company in a research report on Tuesday, March 6th. Jefferies Group set a $145.00 target price on shares of AbbVie and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, Evercore ISI reiterated a “buy” rating and set a $144.00 target price on shares of AbbVie in a research report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $120.96.
In other AbbVie news, VP Robert A. Michael sold 992 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $120.31, for a total transaction of $119,347.52. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Chase sold 70,928 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $117.18, for a total transaction of $8,311,343.04. Following the transaction, the chief financial officer now directly owns 203,391 shares in the company, valued at $23,833,357.38. The disclosure for this sale can be found here. Insiders have sold a total of 211,197 shares of company stock valued at $24,585,575 over the last quarter. 0.23% of the stock is currently owned by company insiders.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.